Harvard Bioscience Stock Current Asset
| HBIO Stock | USD 2.20 0.01 0.46% |
Harvard Bioscience fundamentals help investors to digest information that contributes to Harvard Bioscience's financial success or failures. It also enables traders to predict the movement of Harvard Stock. The fundamental analysis module provides a way to measure Harvard Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harvard Bioscience stock.
At this time, Harvard Bioscience's Total Current Assets are very stable compared to the past year. As of the 29th of November 2024, Other Current Assets is likely to grow to about 6.2 M, while Non Current Assets Total are likely to drop about 73.6 M. Harvard | Current Asset |
Harvard Bioscience Company Current Asset Analysis
Harvard Bioscience's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Harvard Bioscience Current Asset | 50.55 M |
Most of Harvard Bioscience's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Harvard Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Harvard Current Asset Historical Pattern
Today, most investors in Harvard Bioscience Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Harvard Bioscience's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Harvard Bioscience current asset as a starting point in their analysis.
Harvard Bioscience Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Harvard Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Harvard Bioscience has a Current Asset of 50.55 M. This is 97.65% lower than that of the Life Sciences Tools & Services sector and 95.53% lower than that of the Health Care industry. The current asset for all United States stocks is 99.46% higher than that of the company.
Harvard Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harvard Bioscience's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harvard Bioscience could also be used in its relative valuation, which is a method of valuing Harvard Bioscience by comparing valuation metrics of similar companies.Harvard Bioscience is currently under evaluation in current asset category among its peers.
Harvard Bioscience ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Harvard Bioscience's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Harvard Bioscience's managers, analysts, and investors.Environmental | Governance | Social |
Harvard Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0198 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 137.08 M | ||||
| Shares Outstanding | 43.62 M | ||||
| Shares Owned By Insiders | 7.77 % | ||||
| Shares Owned By Institutions | 73.88 % | ||||
| Number Of Shares Shorted | 374.06 K | ||||
| Price To Earning | (25.00) X | ||||
| Price To Book | 1.47 X | ||||
| Price To Sales | 0.98 X | ||||
| Revenue | 112.25 M | ||||
| Gross Profit | 62.29 M | ||||
| EBITDA | 8.03 M | ||||
| Net Income | (3.42 M) | ||||
| Cash And Equivalents | 4.26 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 42.77 M | ||||
| Debt To Equity | 0.73 % | ||||
| Current Ratio | 2.42 X | ||||
| Book Value Per Share | 1.50 X | ||||
| Cash Flow From Operations | 14.03 M | ||||
| Short Ratio | 2.57 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Price To Earnings To Growth | 2.89 X | ||||
| Target Price | 6.25 | ||||
| Number Of Employees | 391 | ||||
| Beta | 1.31 | ||||
| Market Capitalization | 95.96 M | ||||
| Total Asset | 137.37 M | ||||
| Retained Earnings | (145.6 M) | ||||
| Working Capital | 22.5 M | ||||
| Current Asset | 50.55 M | ||||
| Current Liabilities | 19.32 M | ||||
| Net Asset | 137.37 M |
About Harvard Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harvard Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harvard Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harvard Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Harvard Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Harvard Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Harvard Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Harvard Bioscience Stock: Check out Harvard Bioscience Piotroski F Score and Harvard Bioscience Altman Z Score analysis. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.